PwC's Next in Health

Hosted by PwC's Health Industries

Business Management Health Fitness

Website RSS feed

Episodes

Latest episode

Oct 2026

Language

EN-US

About the show

Hosted by Glenn Hunzinger, US Health Industries Leader, the Next in Health podcast series offers insights on the most important issues facing pharma, medtech, and healthcare. PwC business leaders discuss the latest trends and their impact on health industries, whether it is policy, AI, innovation, care delivery, business model reinvention, or bold moves shaping the future. If it is happening in health industries, we are talking about it.

Listen to episodes

60 recent

November 13, 2026Episode 1119 min

2026 Midterm Election Results: What's Next for US Healthcare Policy?

What do the 2026 midterm election results mean for the future of US healthcare? With Democrats taking control of Congress and a Republican White House, healthcare affordability, access and industry oversight are expected to remain in focus. But how much policy change is actually possible? In this episode of Next in Health, PwC's Glenn Hunzinger is joined by Kelly Griffin, Tamil Sriram and Phil Sclafani to discuss where bipartisan progress may be possible, what increased congressional oversight could mean for the industry, and how payers, providers, pharmaceutical and medtech companies can prepare for what's next. Discussion highlights: What's next for healthcare policy: How Democratic control of Congress could shift policy priorities, increase oversight and influence the debate heading into 2028. Where bipartisan progress is possible: Potential action on affordability, drug pricing, cybersecurity, AI and regulatory modernization. Implications for payers and providers: How coverage uncertainty, reimbursement pressures and increased scrutiny could affect financial and operational strategies. What pharma and medtech should watch: Drug pricing, regulatory developments and the impact of customer financial pressures on access, adoption and investment. How healthcare leaders can prepare: Why scenario planning, operational efficiency, consumer trust and demonstrating value remain critical amid policy uncertainty. Speakers: Glenn Hunzinger, US Health Industries Leader, PwC Kelly Griffin, Director, Health Policy and Intelligence Institute, PwC Tamil Sriram, Principal, Health Industries Risk & Regulatory, PwC Philip Sclafani, Principal, Pharmaceutical and Life Sciences, PwC Read our latest report: https://www.pwc.com/us/en/america-in-motion/2026-midterm-elections.html For more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.

October 15, 2026Episode 1023 min

Bringing medtech innovation to market (Part 2)

Bringing medtech innovation to market requires more than a breakthrough technology. It takes the right capital, evidence, reimbursement strategy, and path to scale. In this episode of PwC’s Next in Health, Glenn Hunzinger and Brent Hill continue their conversation with Darshana Zaveri, co-founder and managing partner of Catalyst Health Ventures, and Geoff Pardo, general partner at Gilde Healthcare, exploring what it takes to turn promising medtech innovation into sustainable growth and patient impact. From funding and clinical evidence to M&A, product-market fit, and capital efficiency, the conversation examines how founders, investors, and strategic players are navigating an increasingly complex market. Discussion highlights: The evolving funding environment for early-stage medtech companies and what investors are looking for today Why clinical, regulatory, and reimbursement strategies increasingly need to be considered together The forces driving medtech M&A, including portfolio optimization, new buyers, and the need for growth How companies and investors can build toward meaningful value inflection points and potential exits The importance of capital discipline, investor alignment, strong leadership teams, and product-market fit Where investors see the greatest opportunities for MedTech innovation over the next three to five years and beyond Speakers: Glenn Hunzinger, US Health Industries Leader, PwC Darshana Zaveri, Co-founder and Managing Partner, Catalyst Health Ventures Geoff Pardo, General Partner, Gilde Healthcare Brent Hill, Managing Director, Medtech Strategy, PwC For more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.

October 8, 2026Episode 933 min

The next wave of medtech innovation (Part 1)

Medtech innovation is accelerating, creating new possibilities for how and where patients receive care. In this episode of PwC’s Next in Health, Glenn Hunzinger and Brent Hill are joined by Darshana Zaveri, co-founder and managing partner of Catalyst Health Ventures, and Geoff Pardo, general partner at Gilde Healthcare, for part one of a two-part conversation on the next wave of medtech innovation. From AI and connected care to less invasive technologies, robotics, and the shift beyond the hospital, the conversation explores the technologies and market trends reshaping medtech and where investors and innovators see the greatest opportunities ahead. Discussion highlights: How medtech innovation is evolving toward less invasive, more scalable, and increasingly connected technologies AI’s growing role in devices, clinical decision-making, and connected care The shift from hospitals to ambulatory settings and the home and what it means for medtech companies Emerging opportunities across neuromodulation, robotics, biomaterials, drug-device combinations, and remote monitoring The balance between creating entirely new categories and building on established markets The growing importance of clinical evidence and data in driving adoption and improving patient care Speakers: Glenn Hunzinger, US Health Industries Leader, PwC Darshana Zaveri, Co-founder and Managing Partner, Catalyst Health Ventures Geoff Pardo, General Partner, Gilde Healthcare Brent Hill, Managing Director, Medtech Strategy, PwC For more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.

July 30, 2026Episode 835 min

Behind the Numbers 2027: Understanding what's driving healthcare costs—and what it means for the future of healthcare

Healthcare affordability continues to be one of the defining challenges facing the industry. In this episode of PwC's Next in Health, Glenn Hunzinger is joined by Thom Bales, Derek Skoog, and Philip Sclafani to discuss the findings from PwC's Behind the Numbers 2027 report and the forces driving medical cost trends toward 9% in 2027. From AI-enabled documentation and provider reimbursement to GLP-1 therapies, behavioral health, and payment integrity, the conversation explores what's contributing to rising costs—and where healthcare leaders can focus to improve affordability while continuing to advance innovation and patient care. Discussion highlights: Medical cost trends approaching 9% and the forces driving healthcare inflation AI's growing influence on clinical documentation, payment integrity, and reimbursement Innovation's impact on affordability, from GLP-1 therapies to cell and gene therapies Strategies health plans, employers, and providers are using to improve affordability and reduce friction The evolving role of reimbursement, utilization management, and payment integrity in managing costs What rising medical costs mean for employers, consumers, and the future of healthcare Speakers: Glenn Hunzinger, US Health Industries Leader, PwC Thom Bales, US Health Services Advisory Leader, PwC Derek Skoog, Principal, Health Services, PwC Philip Sclafani, Principal, Pharmaceutical and Life Sciences, PwC For additional insights, check out our Behind the numbers 2027 report at https://www.pwc.com/us/en/industries/health-industries/library/behind-the-numbers.html For more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.

June 25, 2026Episode 712 min

US Medtech Deals Midyear Outlook 2026: Why companies are investing through uncertainty

Glenn Hunzinger, PwC's US Health Industries Leader, speaks with James Woods, PwC's US MedTech Leader, about the forces shaping MedTech dealmaking in 2026. Despite capital market pressures, supply chain challenges, and geopolitical uncertainty, companies continue to invest in innovation, portfolio transformation, and growth opportunities. The conversation explores where capital is flowing, how companies are reshaping portfolios, and what dealmakers should watch in the months ahead. Discussion highlights: Continued MedTech deal activity despite capital market pressures and economic uncertainty Investment focused on cardiovascular technologies, robotics, connected care, and ecosystem-enabling solutions Portfolio transformation as a driver of growth, shareholder value, and strategic repositioning Connected care's role in improving efficiency, patient outcomes, and healthcare delivery Private equity activity across take-private transactions and portfolio carve-outs Strategic priorities for MedTech leaders balancing organic growth, M&A, and capital allocation Speakers: Glenn Hunzinger, US Health Industries Leader, PwC James Woods, US MedTech Deals Leader, PwC For additional insights on the medtech deals landscape, check out our Medtech: US Deals 2026 midyear outlook https://www.pwc.com/us/en/industries/health-industries/library/medtech-deals-outlook.html For more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.

June 25, 2026Episode 69 min

US Health Services Deals Midyear Outlook 2026: Why investors are focusing on resilience and value creation

Glenn Hunzinger, PwC's US Health Industries Leader, speaks with Dan Farrell, PwC's Health Services Deals Leader, about the forces shaping health services dealmaking in 2026. Despite ongoing reimbursement uncertainty, rising medical costs, and operational pressures, investors continue to deploy capital into assets with strong fundamentals and clear value creation opportunities. The conversation explores where capital is flowing, how AI is influencing investment decisions, and what dealmakers should prioritize in the second half of the year. Discussion Highlights: Resilient health services deal activity despite reimbursement uncertainty and rising medical costs Investor focus on operational resilience, earnings durability, and clear value creation pathways Continued momentum in physician medical groups and behavioral health organizations AI's growing role in diligence, operational performance, and value creation strategies Increased activity in portfolio optimization, carve-outs, and strategic capital allocation Key priorities for dealmakers navigating growth and value creation in the second half of 2026 Speakers: Glenn Hunzinger, US Health Industries Leader, PwC Dan Farrell, US Health services Deals leader, PwC For additional insights on the health services deals landscape, check out our Health services: US Deals 2026 midyear outlook available now: https://www.pwc.com/us/en/industries/health-industries/library/health-services-deals-outlook.html For more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.

June 24, 2026Episode 513 min

US Pharma Deals Midyear Outlook 2026: Why Dealmakers Are Leaning Into Growth

Glenn Hunzinger, PwC's US Health Industries Leader, speaks with Dan Farrell, PwC's Health Services Deals Leader, about the forces shaping health services dealmaking in 2026. Despite ongoing reimbursement uncertainty, rising medical costs, and operational pressures, investors continue to deploy capital into assets with strong fundamentals and clear value creation opportunities. The conversation explores where capital is flowing, how AI is influencing investment decisions, and what dealmakers should prioritize in the second half of the year. Discussion Highlights: Resilient health services deal activity despite reimbursement uncertainty and rising medical costs Investor focus on operational resilience, earnings durability, and clear value creation pathways Continued momentum in physician medical groups and behavioral health organizations AI's growing role in diligence, operational performance, and value creation strategies Increased activity in portfolio optimization, carve-outs, and strategic capital allocation Key priorities for dealmakers navigating growth and value creation in the second half of 2026 Speakers: Glenn Hunzinger, US Health Industries Leader, PwC Roel Van den Akker, US Pharma and Life Science Deals Leader, PwC For additional insights on the pharmaceutical and life sciences deals landscape, check out our Pharmaceutical and Life Sciences: US Deals 2026 Midyear Outlook report , available now: https://www.pwc.com/us/en/industries/health-industries/library/pharma-life-sciences-deals-outlook.html For more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.

May 4, 2026Episode 417 min

What to Watch in US Health Policy Before the 2026 Midterms

As the 2026 midterm elections approach, healthcare leaders are asking whether this is just another policy cycle or a more pivotal moment in an increasingly complex and fragmented landscape. In this episode of PwC’s Next in Health, Glenn Hunzinger speaks with Kelly Griffin and Philip Sclafani about how shifting policy dynamics, persistent cost pressures, and rapid industry transformation are reshaping strategy across the healthcare ecosystem. Discussion highlights: Why the 2026 midterms are less about sweeping reform and more about signaling the direction of the operating environment How affordability, transparency, and increased state-level action are shaping policy and driving industry change Why healthcare costs continue to rise and why traditional levers may not be enough to bend the cost curve How pharma, payers, and providers are adapting business models amid regulatory pressure and evolving market dynamics The growing role of AI, partnerships, and ecosystem convergence in accelerating transformation What healthcare leaders should prioritize, from policy intelligence and scenario planning to operating effectively in a more fragmented environment Speakers: Glenn Hunzinger, US Health Industries Leader, PwC Kelly Griffin, Director, Health Policy and Intelligence Institute, PwC Philip Sclafani, Principal, Pharmaceutical and Life Sciences, PwC For more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.

March 17, 2026Episode 320 min

Strategies for accessing funding and managing risk in rural health transformation

With $50 billion flowing through the Rural Health Transformation Program (RHTP), healthcare leaders are questioning whether this marks short term stabilization or a real opportunity to redesign rural care. In this episode of PwC’s Next in Health, Glenn Hunzinger speaks with Thom Bales and Jill Olmstead about how states are deploying funds, how accountability is shaping execution, and what sustainable rural transformation could look like. Discussion highlights: Why the RHTP differs from prior relief efforts, with funding tied to measurable outcomes and accountability How states are prioritizing workforce sustainability, value based care, and regional partnerships The role of technology, telehealth, shared data infrastructure, and AI in expanding access and modernizing rural delivery models What successful execution requires across governance, compliance, milestone tracking, and multi state coordination Why provider engagement with state strategies and ecosystem collaboration will be critical to success What durable rural transformation could look like over the next three to five years Speakers: Glenn Hunzinger, US Health Industries Leader, PwC Thom Bales, US Health Services Advisory Leader, PwC Jill Olmstead, Principal, Health Services, PwC You can access the full report here: https://www.pwc.com/us/en/industries/health-industries/health-policy-and-intelligence-institute/ruralhealth.html For more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.

February 9, 2026Episode 224 min

2026 Healthcare Investment Trends

From the JPM Healthcare Conference in San Francisco, Glenn Hunzinger, PwC’s Health Industries Leader, speaks with Jeremy Gelber, Partner at Vitruvian Partners, and Claire Love, Principal in PwC’s Deals Strategy practice to explore where healthcare investment momentum is building for 2026, how technology is reshaping value creation, and what investors are watching as care models, consumer behavior, and capital deployment continue to evolve. Discussion highlights: Where technology and AI are delivering near term returns by improving efficiency, reducing administrative friction, and streamlining care delivery and payment Why women’s health is gaining attention as an underinvested growth opportunity, driven by unmet need, changing consumer expectations, and attractive long term economics How regulatory uncertainty is influencing investment decisions, increasing the importance of scenario planning and flexibility Where deal activity is expected to pick up in 2026 across healthcare subsectors, including healthcare IT, pharma services, medtech, diagnostics, and biotech How consumer trust, access to health data, and evolving behavior are shaping future care models and investment priorities Speakers: Glenn Hunzinger, US Health Industries Leader, PwC Jeremy Gelber, Partner, Vitruvian Partners Claire Love, Deals Strategy Principal, PwC This episode is also available as a video on our website: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast/2026-healthcare-investment-trends.html For more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.